OncoMatch/Clinical Trials/NCT03911388
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Is NCT03911388 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies G207 for neoplasms, brain.
Treatment: G207 — This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: surgery
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Must have received: radiation therapy
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Must have received: chemotherapy
progressive or recurrent despite standard care including surgery, radiotherapy, and/or chemotherapy
Lab requirements
Blood counts
absolute neutrophil count > 1000/mm3, platelets > 100,000/mm3, prothrombin time (pt) or partial thromboplastin time (ptt) < 1.3 x control
Kidney function
creatinine within normal institutional limits or creatinine clearance >60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal
Liver function
total bilirubin < 1.5 mg/dl, transaminases < 3 times above the upper limits of the institutional norm
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's of Alabama · Birmingham, Alabama
- St. Louis Children's Hospital · St Louis, Missouri
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify